



Letter to the editor regarding Gholamzad et al., “A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future”

Simon Faissner¹

Received: 12 December 2019 / Revised: 12 December 2019 / Accepted: 18 December 2019 / Published online: 11 January 2020
© The Author(s) 2020

Dear Sirs,

In their review entitled “A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future”, Gholamzad et al. also write about the CD25 targeted injectable antibody daclizumab [1]. While the authors correctly describe its mechanism of action and trial data as well as the initial approval status, they, unfortunately, do not state that daclizumab has been retracted from the market in March 2018 due to 12 cases of serious inflammatory brain disorders, including encephalitis and meningoencephalitis with three fatal cases [2]. The mechanism of secondary autoimmunity is until now not entirely understood. One explanation for the development of daclizumab-associated secondary autoimmunity might be the fact that the expansion of regulatory T cells and possibly activation induced T-cell apoptosis might be impaired [3]. Therefore, post-marketing vigilance is crucial to ensure safety in patients treated with new medications [4] and learn about new and as of unknown side effects. Since the review appeared online half a year after the retraction of daclizumab from the market, this information certainly should have been included.

Acknowledgments Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest SF received travel Grants from Biogen Idec and Genzyme, speaker or board honoraria from Novartis and Celgene and research support from Novartis, all not related to the content of this manuscript.

Responsible Editor: Dr. John Di Battista.

✉ Simon Faissner
simon.faissner@rub.de

¹ Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791 Bochum, Germany

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. *Inflamm Res*. 2019;68(1):25–38. <https://doi.org/10.1007/s00011-018-1185-0>.
2. European Medicines Agency. Multiple sclerosis medicine Zinbryta suspended in the EU. London: European Medicines Agency. Report No. EMA/155367/2018, 8 March 2018.
3. Cohan SL, Lucassen EB, Romba MC, Linch SN. Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis. *Bio-medicines*. 2019. <https://doi.org/10.3390/biomedicines7010018>.
4. Bianchi A, Ciccarelli O. Daclizumab-induced encephalitis in multiple sclerosis. *Multiple Scler (Houndmills, Basingstoke, England)*. 2019;25(12):1557–9. <https://doi.org/10.1177/1352458519845079>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.